Global Antibody Therapeutics and Blood Antibody Therapeutics Market Growth (Status and Outlook) 2023-2029

Global Antibody Therapeutics and Blood Antibody Therapeutics Market Growth (Status and Outlook) 2023-2029

Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.

Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
LPI (LP Information)' newest research report, the “Antibody Therapeutics and Blood Antibody Therapeutics Industry Forecast” looks at past sales and reviews total world Antibody Therapeutics and Blood Antibody Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Antibody Therapeutics and Blood Antibody Therapeutics sales for 2023 through 2029. With Antibody Therapeutics and Blood Antibody Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody Therapeutics and Blood Antibody Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Antibody Therapeutics and Blood Antibody Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody Therapeutics and Blood Antibody Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody Therapeutics and Blood Antibody Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody Therapeutics and Blood Antibody Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody Therapeutics and Blood Antibody Therapeutics.
The global Antibody Therapeutics and Blood Antibody Therapeutics market size is projected to grow from US$ 187250 million in 2022 to US$ 371210 million in 2029; it is expected to grow at a CAGR of 10.3% from 2023 to 2029.
The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody Therapeutics and Blood Antibody Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
IgG1
IgG4
Others
Segmentation by application
Autoimmune
Tumor
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Abbvie
Johnson & Johnson
Bristol-Myers Squibb
Novartis
Merck
Alexion Pharmaceuticals
Takeda
Amgen
Biogen
UCB
Eli Lilly and Company
AstraZeneca

Please note: The report will take approximately 2 business days to prepare and deliver.